Project Details
Description
General objective
Formulate the risk factors associated with the development of anti-drug antibodies in patients with non-infectious uveitis treated with adalimumab.
Specific objectives (clinical phase)
•Sociodemographic characterization of patients with non-infectious uveitis treated with adalimumab in two uveitis centers.
•To determine the frequency of anti-adalimumab (AAA+) antibodies in patients with non-infectious uveitis treated with adalimumab.
Formulate the risk factors associated with the development of anti-drug antibodies in patients with non-infectious uveitis treated with adalimumab.
Specific objectives (clinical phase)
•Sociodemographic characterization of patients with non-infectious uveitis treated with adalimumab in two uveitis centers.
•To determine the frequency of anti-adalimumab (AAA+) antibodies in patients with non-infectious uveitis treated with adalimumab.
Keywords
Anti-drug antibodies, anti-Adalimumab antibodies, next generation sequencing, auto-antibodies, uveitis, adalimumab.
| Status | Finished |
|---|---|
| Effective start/end date | 1/17/23 → 1/17/24 |
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
Main Funding Source
- Competitive Funds
- Seed Capital
Location
- Bogotá D.C.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.